Form 4: 2seventy bio Director Denice Torres Reports Disposal of Shares in Merger with Bristol-Myers Squibb

Director Denice Torres reports the disposal of shares and stock options in 2seventy bio following the completion of a merger with Bristol-Myers Squibb, where shares were acquired for $5.00 each.

Summary

• Denice Torres, a director of 2seventy bio, filed a Form 4 detailing changes in beneficial ownership.
• The filing reports the disposal of common stock and stock options due to the merger between 2seventy bio and Bristol-Myers Squibb Company.
• The merger was completed on May 13, 2025, with Bristol-Myers Squibb acquiring all outstanding shares of 2seventy bio for $5.00 per share.
• Shares held by the Reporting Person were tendered in exchange for the Merger Consideration of $5.00 per share.
• Restricted stock units (RSUs) became fully vested and were converted into the right to receive $5.00 per share.
• Stock options with an exercise price less than $5.00 were converted into the right to receive the difference between $5.00 and the exercise price.
• Stock options with an exercise price equal to or greater than $5.00 were cancelled for no consideration.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document simply reports the completion of a merger and the resulting transactions. It doesn't express positive or negative views.

Future Outlook

The merger is complete, and 2seventy bio is now a wholly-owned subsidiary of Bristol-Myers Squibb.

Industry Context

This announcement reflects ongoing consolidation within the biotechnology industry, where larger pharmaceutical companies acquire smaller firms with promising technologies or drug candidates.

Stakeholder Impact

• Shareholders received $5.00 per share as part of the merger agreement.
• Employees may experience changes as 2seventy bio becomes integrated into Bristol-Myers Squibb.

Key Dates

Keywords

Form 4, Merger, Beneficial Ownership, 2seventy bio, Bristol-Myers Squibb, TSVT, Denice Torres